

NEW MEXICO OIL CONSERVATION COMMISSION

Santa Fe, New Mexico

(Form C-104)
Revised 7/1/57REQUEST FOR ~~(OIL)~~ - (GAS) ALLOWABLENew Well
~~Recompletion~~

This form shall be submitted by the operator before an initial allowable will be assigned to any completed Oil or Gas well. Form C-104 is to be submitted in QUADRUPPLICATE to the same District Office to which Form C-101 was sent. The allowable will be assigned effective 7:00 A.M. on date of completion or recompletion, provided this form is filed during calendar month of completion or recompletion. The completion date shall be that date in the case of an oil well when new oil is delivered into the stock tanks. Gas must be reported on 15.025 psia at 60° Fahrenheit.

Dallas, Texas

11-17-59

(Place)

(Date)

WE ARE HEREBY REQUESTING AN ALLOWABLE FOR A WELL KNOWN AS:

Arizona Explorations Inc. Jicarilla, Well No. C-6, in NW 1/4 NW 1/4,
(Company or Operator) (Lease)

D 3, Sec. 3, T. 23N, R. 5W, NMPM, Ballard PC Pool
Unit Letter

Rio Arriba

County. Date Spudded 9-20-59 Date Drilling Completed 9-29-59

Please indicate location:

Elevation 6697 Total Depth 2372 PBD 2336

Top Oil/Gas Pay 2262 Name of Prod. Form. Pictured Cliffs

PRODUCING INTERVAL -

Perforations 2265-79'

Open Hole - Depth Casing Shoe 2371 Depth Tubing 2277

OIL WELL TEST -

Natural Prod. Test: bbls. oil, bbls water in hrs, min. Size Choke

Test After Acid or Fracture Treatment (after recovery of volume of oil equal to volume of Choke load oil used): bbls. oil, bbls water in hrs, min. Size

GAS WELL TEST -

Natural Prod. Test: - MCF/Day; Hours flowed Choke Size

Method of Testing (pitot, back pressure, etc.):

Test After Acid or Fracture Treatment: 1,792 MCF/Day; Hours flowed 3

Choke Size 3/4 Method of Testing: Back pressure

Acid or Fracture Treatment (Give amounts of materials used, such as acid, water, oil, and sand): 28,884 gallons water, 40,000# sand

Casing Tubing Date first new Press. Press. oil run to tanks

Oil Transporter

Gas Transporter Southern Union Gas Company

Remarks:

I hereby certify that the information given above is true and complete to the best of my knowledge.

Approved NOV 18 1959, 19

Arizona Explorations Inc.

(Company or Operator)

OIL CONSERVATION COMMISSION

By: C. W. Josey, Jr.
(Signature)

Title: Vice-President

Send Communications regarding well to:

Name: C. W. Josey, Jr.

Address: 418 Meadows Building
Dallas 6, Texas

By: Original Signed Emory C. Arnold

Title: Supervisor Oil # 3

CO-OPERATIVE COMMISSION
DISTRICT OFFICE

100

1. *Pharmaceuticals* (1997) 10: 101-102.
 2. *Pharmaceuticals* (1997) 10: 103-104.
 3. *Pharmaceuticals* (1997) 10: 105-106.
 4. *Pharmaceuticals* (1997) 10: 107-108.
 5. *Pharmaceuticals* (1997) 10: 109-110.
 6. *Pharmaceuticals* (1997) 10: 111-112.
 7. *Pharmaceuticals* (1997) 10: 113-114.
 8. *Pharmaceuticals* (1997) 10: 115-116.
 9. *Pharmaceuticals* (1997) 10: 117-118.
 10. *Pharmaceuticals* (1997) 10: 119-120.
 11. *Pharmaceuticals* (1997) 10: 121-122.
 12. *Pharmaceuticals* (1997) 10: 123-124.
 13. *Pharmaceuticals* (1997) 10: 125-126.
 14. *Pharmaceuticals* (1997) 10: 127-128.
 15. *Pharmaceuticals* (1997) 10: 129-130.
 16. *Pharmaceuticals* (1997) 10: 131-132.
 17. *Pharmaceuticals* (1997) 10: 133-134.
 18. *Pharmaceuticals* (1997) 10: 135-136.
 19. *Pharmaceuticals* (1997) 10: 137-138.
 20. *Pharmaceuticals* (1997) 10: 139-140.
 21. *Pharmaceuticals* (1997) 10: 141-142.
 22. *Pharmaceuticals* (1997) 10: 143-144.
 23. *Pharmaceuticals* (1997) 10: 145-146.
 24. *Pharmaceuticals* (1997) 10: 147-148.
 25. *Pharmaceuticals* (1997) 10: 149-150.
 26. *Pharmaceuticals* (1997) 10: 151-152.
 27. *Pharmaceuticals* (1997) 10: 153-154.
 28. *Pharmaceuticals* (1997) 10: 155-156.
 29. *Pharmaceuticals* (1997) 10: 157-158.
 30. *Pharmaceuticals* (1997) 10: 159-160.
 31. *Pharmaceuticals* (1997) 10: 161-162.
 32. *Pharmaceuticals* (1997) 10: 163-164.
 33. *Pharmaceuticals* (1997) 10: 165-166.
 34. *Pharmaceuticals* (1997) 10: 167-168.
 35. *Pharmaceuticals* (1997) 10: 169-170.
 36. *Pharmaceuticals* (1997) 10: 171-172.
 37. *Pharmaceuticals* (1997) 10: 173-174.
 38. *Pharmaceuticals* (1997) 10: 175-176.
 39. *Pharmaceuticals* (1997) 10: 177-178.
 40. *Pharmaceuticals* (1997) 10: 179-180.
 41. *Pharmaceuticals* (1997) 10: 181-182.
 42. *Pharmaceuticals* (1997) 10: 183-184.
 43. *Pharmaceuticals* (1997) 10: 185-186.
 44. *Pharmaceuticals* (1997) 10: 187-188.
 45. *Pharmaceuticals* (1997) 10: 189-190.
 46. *Pharmaceuticals* (1997) 10: 191-192.
 47. *Pharmaceuticals* (1997) 10: 193-194.
 48. *Pharmaceuticals* (1997) 10: 195-196.
 49. *Pharmaceuticals* (1997) 10: 197-198.
 50. *Pharmaceuticals* (1997) 10: 199-200.
 51. *Pharmaceuticals* (1997) 10: 201-202.
 52. *Pharmaceuticals* (1997) 10: 203-204.
 53. *Pharmaceuticals* (1997) 10: 205-206.
 54. *Pharmaceuticals* (1997) 10: 207-208.
 55. *Pharmaceuticals* (1997) 10: 209-210.
 56. *Pharmaceuticals* (1997) 10: 211-212.
 57. *Pharmaceuticals* (1997) 10: 213-214.
 58. *Pharmaceuticals* (1997) 10: 215-216.
 59. *Pharmaceuticals* (1997) 10: 217-218.
 60. *Pharmaceuticals* (1997) 10: 219-220.
 61. *Pharmaceuticals* (1997) 10: 221-222.
 62. *Pharmaceuticals* (1997) 10: 223-224.
 63. *Pharmaceuticals* (1997) 10: 225-226.
 64. *Pharmaceuticals* (1997) 10: 227-228.
 65. *Pharmaceuticals* (1997) 10: 229-230.
 66. *Pharmaceuticals* (1997) 10: 231-232.
 67. *Pharmaceuticals* (1997) 10: 233-234.
 68. *Pharmaceuticals* (1997) 10: 235-236.
 69. *Pharmaceuticals* (1997) 10: 237-238.
 70. *Pharmaceuticals* (1997) 10: 239-240.
 71. *Pharmaceuticals* (1997) 10: 241-242.
 72. *Pharmaceuticals* (1997) 10: 243-244.
 73. *Pharmaceuticals* (1997) 10: 245-246.
 74. *Pharmaceuticals* (1997) 10: 247-248.
 75. *Pharmaceuticals* (1997) 10: 249-250.
 76. *Pharmaceuticals* (1997) 10: 251-252.
 77. *Pharmaceuticals* (1997) 10: 253-254.
 78. *Pharmaceuticals* (1997) 10: 255-256.
 79. *Pharmaceuticals* (1997) 10: 257-258.
 80. *Pharmaceuticals* (1997) 10: 259-260.
 81. *Pharmaceuticals* (1997) 10: 261-262.
 82. *Pharmaceuticals* (1997) 10: 263-264.
 83. *Pharmaceuticals* (1997) 10: 265-266.
 84. *Pharmaceuticals* (1997) 10: 267-268.
 85. *Pharmaceuticals* (1997) 10: 269-270.
 86. *Pharmaceuticals* (1997) 10: 271-272.
 87. *Pharmaceuticals* (1997) 10: 273-274.
 88. *Pharmaceuticals* (1997) 10: 275-276.
 89. *Pharmaceuticals* (1997) 10: 277-278.
 90. *Pharmaceuticals* (1997) 10: 279-280.
 91. *Pharmaceuticals* (1997) 10: 281-282.
 92. *Pharmaceuticals* (1997) 10: 283-284.
 93. *Pharmaceuticals* (1997) 10: 285-286.
 94. *Pharmaceuticals* (1997) 10: 287-288.
 95. *Pharmaceuticals* (1997) 10: 289-290.
 96. *Pharmaceuticals* (1997) 10: 291-292.
 97. *Pharmaceuticals* (1997) 10: 293-294.
 98. *Pharmaceuticals* (1997) 10: 295-296.
 99. *Pharmaceuticals* (1997) 10: 297-298.
 100. *Pharmaceuticals* (1997) 10: 299-300.
 101. *Pharmaceuticals* (1997) 10: 301-302.
 102. *Pharmaceuticals* (1997) 10: 303-304.
 103. *Pharmaceuticals* (1997) 10: 305-306.
 104. *Pharmaceuticals* (1997) 10: 307-308.
 105. *Pharmaceuticals* (1997) 10: 309-310.
 106. *Pharmaceuticals* (1997) 10: 311-312.
 107. *Pharmaceuticals* (1997) 10: 313-314.
 108. *Pharmaceuticals* (1997) 10: 315-316.
 109. *Pharmaceuticals* (1997) 10: 317-318.
 110. *Pharmaceuticals* (1997) 10: 319-320.
 111. *Pharmaceuticals* (1997

[illegible]

11/11/1964

1. The first step in the process is to identify the problem or issue that needs to be addressed. This involves gathering information and understanding the context of the problem.

1

10-10-68